1. Home
  2. CNF vs CURX Comparison

CNF vs CURX Comparison

Compare CNF & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNF

CNFinance Holdings Limited each representing twenty (20)

HOLD

Current Price

$5.98

Market Cap

35.7M

Sector

Finance

ML Signal

HOLD

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$0.43

Market Cap

29.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNF
CURX
Founded
1999
2018
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.7M
29.7M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
CNF
CURX
Price
$5.98
$0.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.5K
2.7M
Earning Date
08-28-2025
09-09-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,241,013.00
N/A
Revenue This Year
$252.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.36
$3.61
52 Week High
$13.90
$8.60

Technical Indicators

Market Signals
Indicator
CNF
CURX
Relative Strength Index (RSI) 60.55 N/A
Support Level $5.60 N/A
Resistance Level $6.10 N/A
Average True Range (ATR) 0.27 0.00
MACD 0.02 0.00
Stochastic Oscillator 90.00 0.00

Price Performance

Historical Comparison
CNF
CURX

About CNF CNFinance Holdings Limited each representing twenty (20)

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.

Share on Social Networks: